Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Brazil's first multidisciplinary consensus on male hypogonadism draws a firm line on who actually qualifies for testosterone replacement therapy. Developed by leading urology, endocrinology, and sexual medicine societies, it requires confirmed sexual dysfunction symptoms and two fasting morning testosterone tests before treatment begins. The guidelines also flag key contraindications and stress that functional hypogonadism may be reversible without TRT.
Brazil's first multidisciplinary consensus on male hypogonadism is pushing back on the casual use of testosterone for muscle gain or aesthetics. Developed jointly by the Brazilian Society of Endocrinology and Metabolism, the Brazilian Society of Urology, and the Brazilian Association for Sexual Medicine and Health, the guidelines lay out a clear, stepwise framework for diagnosing and treating testosterone deficiency in men.
The consensus insists that investigation should only begin when a patient presents with sexual dysfunction symptoms—specifically decreased libido, erectile dysfunction, or reduced spontaneous erections. Nonspecific complaints like mood changes, gynecomastia, or abdominal fat alone don't make the cut. Diagnosis requires two fasting morning testosterone draws, at least four weeks apart, with results interpreted in defined ranges.
Key Takeaways:
Why it matters: With testosterone misuse on the rise, these evidence-based criteria give clinicians—especially GPs, geriatricians, and cardiologists—a structured, defensible framework for both prescribing and withholding TRT, protecting patients from unnecessary treatment and its associated risks.
